Left Atrial Appendage Occlusion Registry (LAAO Registry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02699957|
Recruitment Status : Recruiting
First Posted : March 7, 2016
Last Update Posted : July 8, 2020
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Procedure: Left Atrial Appendage Occlusion|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||3000 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Left Atrial Appendage Occlusion Registry (LAAO Registry)|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||January 2026|
|Estimated Study Completion Date :||January 2026|
Those patients with the condition of atrial fibrillation.
Procedure: Left Atrial Appendage Occlusion
Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
- Proportion of patients with a major complication [ Time Frame: Assessed in hospital for any occurence from the start of procedure date and time until discharge date and time, assessed up to 24 months. Reported quarterly. ]Proportion of patients experiencing any of the following events: Procedure aborted, conversion to open heart, hemorrhagic, ischemic or undetermined stroke, any effusion requiring drainage or surgery, device embolization, systemic embolism, or major bleeding event.
- Proportion of patients who experience a stroke (ischemic or hemorrhagic), or systemic embolism or death after left atrial appendage occlusion during the follow up timeframes [ Time Frame: Assessed at 45 day, 6 month, 1 year and 2 year follow up ]Follow up metric for the proportion of patients who experience a stroke (ischemic or hemorrhagic), or systemic embolism or death after left atrial appendage occlusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02699957
|Contact: Mark Fox, CHC, CHPCemail@example.com|
|Contact: Christina Koutras, RN, BSNfirstname.lastname@example.org|
|United States, District of Columbia|
|American College of Cardiology/National Cardiovascular Data Registry (NCDR)||Recruiting|
|Washington, District of Columbia, United States, 20037|
|Contact: NCDR Product Support 800-257-4737 email@example.com|
|Study Chair:||Paul Varosy, MD||VA Eastern Colorado Health Care System|